Metabolism of the neuroprotectant ergothioneine as a blood-based biomarker of cognitive resilience to amyloid pathology

Joyce R. Chong [a,b], Irwin K. Cheah [c,d], Richard M. Tang [c,d], Barry Halliwell [c,d], Christopher P. Chen [a,b], Mitchell K.P. Lai [a,b,*]

Author Affiliations:
[a]Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore

[b]Memory Aging and Cognition Centre, National University Health System, Singapore 117577, Singapore

[c]Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore

[d]Life Science Institute, Neurobiology Programme, Centre for Life Sciences, National University of Singapore, Singapore 117456, Singapore

Corresponding Author:
Mitchell K.P. Lai, PhD, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Unit 09-01, Centre for Translational Medicine (MD6), 14 Medical Drive, Singapore, 117599 Singapore (mitchell.lai@dementia-research.org)

ORCID: 0000-0001-7685-1424

KEYWORDS: Alzheimer's disease; Antioxidants; Biomarkers; Cognitive resilience; L-Ergothioneine;

Abstract

Background: The mechanisms underlying cognitive resilience to Alzheimer's disease (AD) pathology are under active investigation. The association between dietary micronutrients with neuroprotective properties and cognitive resilience is currently unknown.

Objective: To investigate whether plasma L-ergothioneine (ET), its metabolite L-hercynine (HC), as well as their ratio (HC:ET, as an index of ET metabolism) affect the association between plasma markers of brain amyloid pathology (phosphorylated tau species) and cognitive decline.

Design, setting and participants: This study consisted of 259 dementia-free participants (mean age [SD] = 72 [8] years; 50% females) recruited from memory clinics and the community in Singapore from August 2010 to July 2019 as part of a larger, ongoing longitudinal cohort study on dementia, with analyses performed in February 2025.

Measurements: All participants of this study were dementia-free at baseline (median Clinical Dementia Rating-Sum of Boxes (CDR-SB) [IQR] scores = 0 [1]), had blood collected for measurements of plasma ET, HC, HC:ET, p-tau181 and p-tau217, and underwent annual neuropsychological assessments for up to 5 years (mean follow-up [SD] = 52 [15] months). The main cognitive outcomes were cognitive decline, defined by annual change of CDR-SB, and risk of incident cognitive decline, defined as Global CDR scores (CDR-GS) increments of ≥ 0.5 at follow-up. Linear regression analyses tested for interaction effects of plasma ET, HC and HC:ET on the association between plasma p-tau and cognitive decline, while Cox proportional hazards models were fitted to estimate hazard ratios (HRs) of incident cognitive decline.

Results: Plasma HC:ET significantly moderated associations between plasma p-tau181 and cognitive decline, whereby only High HC:ET attenuated the detrimental effects of plasma p-tau181 on cognitive decline (High HC:ET β = 0.0976; 95% Confidence Interval [CI] = -0.444 to 0.639 vs. Low HC:ET β = 0.849; 95% CI, 0.318 to 1.38). Among

participants with high risk of amyloid pathology, those with Low HC:ET had approximately twofold increased risk of cognitive decline (Hazards ratio [HR] = 1.96; 95% CI = 1.01 to 3.79) compared to participants with High HC:ET (HR=0.87; 95% CI = 0.33 to 2.26) over the follow-up period.

Conclusions: Identification of plasma HC:ET as a biomarker of cognitive resilience to amyloid pathology suggests potential beneficial effects of ET metabolism. Further studies are needed to elucidate ET-mediated neuroprotective mechanisms as potential therapeutic targets in delaying or moderating AD-associated cognitive decline.

1. Introduction

Although Alzheimer's disease (AD) pathology is closely associated with cognitive decline, some individuals remain cognitively intact despite substantial pathological burden [1]. This observed discrepancy between severity of brain pathology and cognitive trajectory gave rise to the concept of cognitive resilience, which refers to the capacity of the brain to maintain cognition and function with aging and disease [2, 3]. In the context of AD, cognitive resilience may be operationalized as the multiple adapted or innate properties and processes at the molecular, cellular and network levels which enable individuals to have better-than-expected cognitive performance despite the severity of amyloid or tau pathology. While initial studies have investigated sociobehavioral, neuroimaging and genetic factors of cognitive resilience [4], the putative biological mechanisms underlying cognitive resilience have more recently begun receiving more research attention, with reports suggesting involvement of neuroinflammation, neurogenesis, cellular repair, mitochondrial, vascular and synaptic functions [5-7]. In contrast, there are few studies directly measuring oxidative stress-associated markers in cognitive resilience. Considering the established pathogenic roles played by oxidative stress in both the neuropathologic hallmarks of amyloid plaques and neurofibrillary tangles, as well as in the frequently concomitant features of neuroinflammation and cerebrovascular disease (CeVD) [8-11], it is worth investigating whether the regulation and balance between pro-oxidant and antioxidant mediators or processes may underlie cognitive resilience versus decline in AD. We have previously reported deficits in plasma levels of the diet-derived micronutrient L-ergothioneine (ET), originally characterized as a strong antioxidant [12], which correlated with both neurodegeneration and CeVD in participants with dementia [13]. However, whether changes of ET and associated biomarkers may mediate cognitive resilience are at present unknown. In this biomarker study, we assessed plasma ET, its metabolite L-hercynine (HC), and their ratio (HC:ET) in a cohort of longitudinally assessed participants who were dementia-free at baseline, and investigated their effects on the established relationship between well-established plasma biomarkers of brain amyloid burden and cognitive decline.

2. Methods

2.1. Study cohort and clinical assessments

Detailed descriptions of the study cohort have been previously reported [13]. Briefly, the 259 dementia-free participants for this study were recruited from memory clinics and the community in Singapore from August 2010 to July 2019 as part of a larger longitudinal cohort study of dementia (n = 700). Participants were given detailed laboratory and clinical assessments including apolipoprotein E (*APOE*) genotyping, demographic and risk factor information, as well as a comprehensive neuropsychological test battery to derive clinical subgroups (see **Supplementary Method S1 & Supplementary Table S1**). Participants were categorized as having No Cognitive Impairment (NCI) if they did not demonstrate objective cognitive impairment on the battery at baseline. Cognitive Impairment No Dementia (CIND) was determined by the presence of impairment in one or more of the above-listed cognitive domains (defined by a score of at least 1.5 standard deviations below established education-adjusted cut-off values on any component test) at baseline, without loss of independent daily function, and not fulfilling the criteria of dementia diagnosis based on the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). Additionally, Clinical Dementia Rating (CDR) assessments were performed at baseline and annual follow-up visits for up to 5 years. For cognitive decline, the primary outcome measure was CDR Sum of Boxes (CDR-SB) slopes, defined as the annual change in CDR-SB (see **Supplementary Method S2**), while the secondary outcome was risk of future cognitive decline, defined by $\geqslant$0.5 increment in CDR Global Score (CDR-GS) at any annual follow-up compared to baseline. As this study focuses on cognitive resilience, only dementia-free (NCI and CIND) participants at baseline were included (see participant flowchart in **Supplementary Figure S1**). This study conforms to the Declaration of Helsinki, with ethics approval from the National Healthcare Group Domain-Specific Review Board (reference numbers 2018/01098 and 2010/00017). Written informed consent was obtained from all participants or their next-of-kin prior to study enrolment.

2.2. Plasma biomarker measurements

Details on blood collection, processing and storage were previously published [14]. Measurements of plasma tau phosphorylated at threonine-181 (p-tau181), an established marker of brain amyloid pathology [15], were performed on the Quanterix Simoa® HD-1 analyzer using commercially available P-Tau181 Advantage V2 assay kits (Quanterix Corporation, Cambridge, MA, USA), per manufacturer's protocol. Plasma p-tau 217 was measured on a NUcleic acid Linked Immuno-Sandwich Assay (NULISA) platform [16] using the commercially available NULISASeq™ CNS Disease Panel (Alamar Biosciences, Fremont, CA, USA). Raw data were normalized using internal and inter-plate controls, rescaled, and log-2 transformed to derive NULISA Protein Quantification (NPQ) units. Reference ranges for amyloid positron emission tomography (PET) positivity was determined by a three-range cut-off approach based on participants within the local cohort with plasma p-tau181, p-tau217 and amyloid PET data available (see **Supplementary Figures S2 and S3**). Plasma ET and HC were measured using liquid chromatography-tandem mass spectrometry (LC–MS/MS) as previously described [13] (see **Supplementary Method S3**), and subsequently dichotomized into Low or High ET, HC and HC:ET using their respective cohort-wide median values as cutoffs, which were 756.35nM, 11.54nM and 0.01417 respectively.

2.3. Statistical analysis

Statistical analysis was performed using R (version 4.4.0, R Core Team) and SPSS Statistics (version 29, International Business Machines Corporation, Armonk, NY). Correlation analyses were performed using Spearman rank correlations. Group comparisons were performed using Mann-Whitney U tests. For the primary outcome, we used linear regression to interrogate interaction effects of High vs. Low levels of plasma ET, HC or HC:ET on the association between plasma p-tau181 and rate of cognitive decline (CDR-SB slope), where a significant interaction effect indicated that the strength of correlation between plasma p-tau181 and cognitive decline differs depending on the level of plasma ET, HC or HC:ET. Cox proportional hazards regression models were used for the secondary outcome of incident cognitive decline, where time to event was defined as the timepoint at which a participant's CDR-GS had increased by ≥0.5 points compared

to baseline. All regression models were adjusted for age, sex, education, *APOE* ε4 status, hypertension, hyperlipidemia, diabetes, cardiovascular disease and baseline CDR-SB. Similar analyses were performed for plasma p-tau217. Results were considered statistically significant at $p<0.05$.

3. Results

3.1. Participant characteristics

Demographic and clinical characteristics of the study cohort are listed in **Table 1**. A total of 259 participants were included in the study. Participants were stratified into Low- (n=142, 55%), Intermediate- (n=67, 26%) and High- (n=50, 19%) risk of amyloid PET positivity (A+) using pre-determined plasma p-tau181 reference ranges (**Supplementary Figure S2**). Measures of longitudinal cognition include CDR-SB slope (change in CDR-SB per year, median [IQR], 0.045 [0.3]) and incident cognitive decline (increment in CDR-GS of ≥0.5, n=91, 35%), over a mean [SD] follow-up duration of 52 [15] months.

3.2. Correlations among plasma biomarkers, brain amyloid and cognitive decline

Plasma p-tau181 levels expectedly correlated with PET amyloid marker Pittsburgh compound B's standardized uptake value ratio (PiB-PET SUVr, rho=0.653, $p<0.001$; **Figure 1A**). Furthermore, cognitive decline (as measured by the CDR-SB slope) positively correlated with PiB-PET SUVr (rho=0.387, p=0.035) and plasma p-tau181 (rho=0.298, $p<0.001$); but negatively correlated with ET (rho=-0.172, p=0.005); HC (rho=-0.293, $p<0.001$) and HC:ET (rho=-0.134, p=0.031, **Figures 1B to 1F**). As another phosphorylated tau species, p-tau217 has been reported to have superior clinical utility as a marker of amyloid pathology [17, 18], we analyzed plasma p-tau217 measured with the NULISA platform, and confirmed that it strongly correlated with plasma p-tau181 concentrations (rho = 0.798, $p<0.001$), PiB-PET SUVr (rho = 0.758, $p<0.001$), and CDR-SB slope (rho = 0.380, $p<0.001$, see **Supplementary Figure 4**). Taken together, our data support the use of phosphorylated tau species as markers of brain amyloid pathology, and further suggest that lower levels of plasma ET, HC and HC:ET are all associated with faster cognitive decline.

3.3. Association between plasma p-tau levels and cognitive decline differs between High vs. Low plasma L-hercynine to L-ergothioneine ratio

After adjustment for covariates, interaction between HC:ET with log-transformed plasma p-tau181 levels remained significant ($P_{interaction}$=0.042). Specifically, HC:ET moderated the association between plasma p-tau181 levels and cognitive decline, such that participants with High HC:ET showed attenuated cognitive decline with increasing plasma p-tau181 (β=0.0976; 95% CI= -0.444 to 0.639); while those with Low HC:ET showed the expected positive correlation between cognitive decline and plasma p-tau181 (β=0.849; 95% CI= 0.318 to 1.38, see **Figure 2A**). In contrast, no significant interactions were observed for ET ($P_{interaction}$=0.937) and HC ($P_{interaction}$=0.182; **Supplementary Table S2**). In sensitivity analyses, repeating the regressions of cognitive decline with non-log-transformed plasma p-tau181 or with p-tau217 showed similar moderation effects by HC:ET (**Supplementary Figures S5A and S5B respectively**).

3.4. Risk of incident cognitive decline in participants at high risk of amyloid PET positivity is affected by the plasma L-hercynine to L-ergothioneine ratio

Using plasma p-tau181 cut-offs to identify participants at Low- (plasma p-tau181 ⩽2.34pg/mL) or High-risk (plasma p-tau181⩾3.61pg/mL) for amyloid PET positivity (A+), Cox regression analyses (**Supplementary Table S3**) of participants with High A+ risk showed that those with Low HC:ET had an approximately twofold increased risk of incident cognitive decline over the follow-up period (Hazard ratio [HR] =1.96; 95% Confidence Interval [CI] =1.01 to 3.79; p=0.047) compared to those with Low A+ risk. In contrast, no increase in risk of incident cognitive decline was observed in High A+ participants with High HC:ET (HR= 0.87; 95% CI=0.33 to 2.26; p=0.770). **Figure 2B** depicts the corresponding Kaplan-Meier survival curves. Similar results were observed when using plasma p-tau217 cut-offs to identify individuals at Low- or High-risk for A+ (**Supplementary Table S4 and Supplementary Figure S6**).

3.5. Higher plasma L-hercynine to L-ergothioneine ratio in cognitively stable participants with high risk of amyloid PET positivity

Finally, we compared plasma ET, HC and HC:ET values between cognitively stable (no change in CDR-GS over the follow-up duration) and cognitively declined (CDR-GS increment of ≥0.5 from baseline over the follow-up duration) participants with High A+ risk. **Figure 3** showed that plasma HC:ET was higher in the cognitively stable group compared to the cognitively declined group (p=0.046), while no corresponding differences were observed for plasma ET (p=0.63) and HC (p=0.16).

4. Discussion

The concept of cognitive resilience as the ability of individuals to maintain brain cognition and function amid aging and disease is gaining increasing momentum in AD research, due to the potential for further insights into neuroprotective mechanisms which can counter AD processes, as well as advancing processes and molecules as potential therapeutic targets. In this context, it is important to recognize that cognitive resilience is a general term which includes cognitive reserve (CR), brain reserve (BR) and brain maintenance (BM), each of which refers to specific aspects of resilience mechanisms, either acquired or innate [2, 3]. In this longitudinal cohort study, we showed that increased plasma L-hercynine to L-ergothioneine ratio (HC:ET) attenuated the cognitive decline typically observed in participants with high risk of brain amyloid positivity, and was also associated with lower risk of incidental cognitive decline for up to five years. These findings suggest that plasma HC:ET may be a novel biomarker of cognitive resilience in AD. Oxidative stress has been recognized as both promoter [19] and consequence [20] of amyloid pathology, and is associated with mitochondrial dysfunction, glucose hypometabolism and neuronal death [21]. L-ergothioneine (ET), a diet-derived histidine derivative, has originally been characterized as a potent antioxidant [12] whose antioxidative effects have been shown to be mediated via oxidation by reactive oxygen species (ROS), thus rendering ET an important scavenger of ROS [22]. Studies have shown L-hercynine (HC) to be a metabolite of ET [23] which can be produced from the desulfurization of ET by ROS, potentially via the formation of sulfonated intermediates [24]. Therefore, HC:ET is postulated to be an index of ET metabolism, and our results suggest that efficient scavenging and countering ROS-associated neurotoxic effects may

be one mechanism by which efficient ET metabolism confers resilience against amyloid pathology-associated cognitive decline.

4.1. Unanswered questions and future work

Although the current findings support ET metabolism-associated antioxidant effects in mediating cognitive resilience to amyloid pathology, a major limitation of this interpretation is the failure of supplementation with common antioxidants like vitamin E in AD interventional trials [25, 26]. Postulated underlying reasons for the lack of efficacy include inadequate target engagement (as brain levels of antioxidants remained low), complex pathophysiology involving multiple processes besides oxidative stress, intervention occurring too late as well as insufficient dosing and duration [26-28]. For some of these drawbacks, ET may offer advantages due to its unique pharmacokinetic properties. For example, the neurophysiological importance of ET is supported by findings that its cognate transporter, organic cation transporter 1 (OCTN1, encoded by *SLC22A4*), is highly expressed in brain parenchyma, accounting for high levels of distribution to neural cells [29, 30] and therefore improving target engagement. Furthermore, ET is differentiated from other antioxidants pharmacodynamically by manifesting a wide range of beneficial effects besides antioxidation, leading them to be called a conditionally essential micronutrient [31], nutraceutical [32], or even a longevity vitamin [33]. Examples of putative neuroprotectant ET effects which may counter AD pathophysiological processes include anti-neuroinflammation, promotion of neuronal differentiation, upregulation of neurotrophic factors, increased dendritic spine formation and inhibition of β-amyloid oligomer formation [22, 30, 33, 34]. However, it is unclear which of the aforementioned mechanism(s) mediate cognitive resilience, and which underlying components (CR, BR or BM) may be involved. Indeed, some purported mechanisms may impinge on more than one component: Using upregulation of neurotrophic factors as an example, this ET effect may affect CR by increasing efficiency of neural networks, but may also involve BR by stimulating synapse structural integrity, as well as BM by maintaining synaptic plasticity processes. Therefore, further work is needed to comprehensively characterize ET metabolism and associated effects which underlie the different components of cognitive resilience.

A second major unanswered question relate to our finding of the inclusion of HC:ET, but not the individual compounds (HC or ET) in moderation analyses (see **Supplementary Table S2**), suggesting that unlike in dementia where ET deficits were evident [13], the baseline efficiency of ET metabolism is the more important factor underlying cognitive resilience. However, the biological factors regulating HC:ET, including functional polymorphic variants of OCTN1, or the potential involvement of gut microbiome known to alter absorption or uptake [25], are at present unknown, and should be further studied to better assess the potential utility of ET-based therapeutic strategies.

4.2. Other Limitations

Whilst plasma phosphorylated tau species, p-tau181 and p-tau217 have been validated as peripheral markers of cortical amyloid burden [15, 35] (also see **Figure 1A and Supplementary Figure S3B**), more established measurements using amyloid PET or cerebrospinal fluid tests were not performed for the entire cohort. Furthermore, our study was conducted on an Asian-based cohort, and findings should be validated in diverse settings to ensure generalizability.

5. Conclusion

A plasma index of L-ergothioneine metabolism may be a biomarker for cognitive resilience amid brain amyloid pathology, indicating the need for further investigations of underlying mechanisms which may involve both well-known antioxidant effects as well as emergent neuroprotective properties. L-Ergothioneine metabolism-associated effects, as well as factors regulating the efficiency of L-ergothioneine metabolism should be further assessed as potential therapeutic targets for cognitive decline and dementia.

CRediT authorship contribution statement

Joyce R. Chong: Writing – review & editing, Writing – original draft, Project administration, Formal analysis, Conceptualization. **Irwin K. Cheah:** Writing – review & editing, Formal analysis. **Richard M. Tang:** Writing – review & editing, Formal analysis. **Barry Halliwell:** Writing – review & editing, Supervision. **Christopher P. Chen:** Writing – review & editing, Funding acquisition, Supervision. **Mitchell K.P. Lai:** Writing – review &

editing, Writing – original draft, Project administration, Funding acquisition, Supervision, Conceptualization.

Funding

National Medical Research Council of Singapore (Grant/Award Number: MOH-000707-01) to Christopher P. Chen; Singapore Ministry of Education Academic Research Fund (Award Number: NUHSRO/2024/028/T1/Seed-Sep23/06) to Mitchell K.P. Lai.

DATA sharing statement

Data cannot be shared publicly because of ethical-legal considerations and consent was not sought from study participants for public data sharing. However, data is available from the corresponding author for researchers who meet the criteria for access to confidential data.

Declaration of generative AI

We declare that no generative AI and AI-assisted technologies were used in this manuscript.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

We are grateful to the patients and their families for their participation in this study. We acknowledge the coordinator and rater teams from the Memory, Ageing and Cognition Centre (MACC), National University Health System, for assistance with participant recruitment and assessments.

Table 1. Descriptive characteristics of the study cohort

Study n	259
Age, years, mean (SD)	72 (8)
Female, n (%)	129 (50)
Education, years, mean (SD)	8 (5)
APOE ε4 carrier, n (%)	66 (26)
Baseline CDR-SB, median (IQR)	0 (1)
Vascular risk factors	
Hypertension, n (%)	171 (66)
Hyperlipidemia, n (%)	197 (76)
Diabetes, n (%)	87 (34)
Cardiovascular disease, n (%)	28 (11)
Plasma biomarkers	
p-tau181, pg/mL, median (IQR)	2.2 (1.5)
L-Hercynine/Ergothioneine ratio, median (IQR)	0.012 (0.02)
Ergothioneine, nM, median (IQR)	915 (955)
L-Hercynine, nM, median (IQR)	13.0 (16)
Plasma p-tau181 derived reference ranges for identifying risk of amyloid PET positivity*	
Low risk (Plasma p-tau181 ≤ 2.34pg/mL)	142 (55)
Intermediate risk (Plasma p-tau181: 2.35pg/mL to 3.60pg/mL)	67 (26)
High risk (Plasma p-tau181 ≥ 3.61pg/mL)	50 (19)
Longitudinal cognitive performance	
CDR-SB slope, change/year, median (IQR)	0.045 (0.3)
Increment in CDR-GS of ≥0.5, n (%)	91 (35)
Follow-up time, months, mean (SD)	52 (15)

*Risk stratified using pre-determined plasma p-tau181 reference ranges (**Supplementary Figure S2**).

Abbreviation: CDR-SB, Clinical Dementia Rating Sum of Boxes; CDR-GS, Clinical Dementia Rating Global Score; CIND, Cognitive Impairment No Dementia; IQR, Interquartile Range; NCI, No Cognitive Impairment; PET, positron emission tomography; SD, Standard Deviation

Figure 1. Correlations amongst blood biomarkers, amyloid burden and cognitive decline



Spearman's correlations between (**A**) plasma p-tau181 and PiB-PET SUVr (as a measurement of cortical amyloid burden); as well as between CDR-SB slope (change in CDR-SB / year, as a measurement of cognitive decline) and (**B**) PiB-PET SUVr, (**C**) plasma p-tau181, (**D**) plasma ET, (**E**) plasma HC, and (**F**) HC to ET ratio (HC : ET). Solid line indicates linear regressed best-fit curve while dashed lines indicate 95% confidence intervals. For better visualization of the graphs, one participant was excluded from the graph in (**D**) (plasma ET=8133.21nM, CDR-SB slope=0.089; rho=-0.174 and p=0.005 after excluding participant from analysis), while two participants were excluded from the graph in (**F**) (HC:ET=0.169, CDR-SB slope=0.14; plasma HC:ET=0.184, CDR-SB slope=-0.054; rho=-0.128 and p=0.040 after excluding participants from analysis). Amyloid PET scans were performed either in the same year as blood collection (n=21), the year following blood collection (n=8), or the year prior to blood collection (n=1). Units for plasma p-tau181 = pg/mL while units for plasma ET and HC = nM.

Abbreviations: *CDR-SB, Clinical Dementia Rating Sum of Boxes; ET, Plasma L-ergothioneine concentration; HC, Plasma L-hercynine concentration; PiB-PET, Pittsburgh Compound B - positron emission tomography; SUVr, Standardized uptake value ratio*

Figure 2. Associations between plasma L-hercynine to L-ergothioneine ratio and cognitive decline



(**A**) Participants with high baseline HC:ET have attenuated CDR-SB slope (change in CDR-SB/year) with increasing plasma p-tau181 (pink line); while those with low HC:ET showed the expected positive correlation between CDR-SB slope and plasma p-tau181 (purple line). High vs. Low HC:ET was dichotomized using the median value. Shaded areas around each regression line represent the 95% confidence intervals for the regression lines. (**B**) Kaplan-Meier curves for participants stratified by Low- vs. High-risk of amyloid PET positivity (A+), with the High-risk group further stratified by plasma levels of HC:ET (Low vs. High). Refer to **Supplementary Figure S2** for the plasma p-tau181 cut-offs to identify participants at Low- (p-tau181⩽2.34pg/mL) or High-risk (p-tau181⩾3.61pg/mL) for A+. Cognitive decline is defined as an increment of CDR-GS of ⩾0.5 from baseline.

Abbreviations: *CDR-GS, Clinical Dementia Rating Global Score; CDR-SB, Clinical Dementia Rating Sum of Boxes; ET, Plasma L-ergothioneine concentration; HC, Plasma L-hercynine concentration*

Figure 3. Plasma biomarkers in cognitive stable versus declining participants at high risk for amyloid PET positivity



Comparison of plasma (**A**) ET; (**B**) HC; and (**C**) HC to ET ratio between cognitively stable (n=29) and declining (n=21) participants with high risk for amyloid PET positivity. Cognitive decline is defined as an increment of CDR-GS of ≥ 0.5 from baseline. High risk of amyloid PET positivity defined by plasma p-tau181 ≥3.61pg/mL (see **Supplementary Figure S2**). Graphs show median values and interquartile range. Group differences were assessed with Mann-Whitney U tests. Units for plasma ET and HC = nM.

Abbreviations: *CDR-GS, Clinical Dementia Rating Global Scores; ET, Plasma L-ergothioneine concentration; HC, Plasma L-hercynine concentration; ns, Not significant*

References

1. Katzman, R., et al., *Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques.* Ann Neurol, 1988. **23**(2): p. 138-44.
2. Stern, Y., et al., *Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance.* Alzheimers Dement, 2020. **16**(9): p. 1305-1311.
3. Stern, Y., et al., *A framework for concepts of reserve and resilience in aging.* Neurobiol Aging, 2023. **124**: p. 100-103.
4. Pappalettera, C., et al., *Cognitive resilience/reserve: Myth or reality? A review of definitions and measurement methods.* Alzheimers Dement, 2024. **20**(5): p. 3567-3586.
5. de Vries, L.E., et al., *The concept of resilience to Alzheimer's Disease: current definitions and cellular and molecular mechanisms.* Mol Neurodegener, 2024. **19**(1): p. 33.
6. Oh, H.S., et al., *A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease.* Nat Med, 2025.
7. Svenningsson, A.L., et al., *Biological mechanisms of resilience to tau pathology in Alzheimer's disease.* Alzheimers Res Ther, 2024. **16**(1): p. 221.
8. Vina, J., C. Borras, and C. Mas-Bargues, *Free radicals in Alzheimer's disease: From pathophysiology to clinical trial results.* Free Radic Biol Med, 2024. **225**: p. 296-301.
9. Bai, R., et al., *Oxidative stress: The core pathogenesis and mechanism of Alzheimer's disease.* Ageing Res Rev, 2022. **77**: p. 101619.
10. Firdous, S.M., S.A. Khan, and A. Maity, *Oxidative stress-mediated neuroinflammation in Alzheimer's disease.* Naunyn Schmiedebergs Arch Pharmacol, 2024. **397**(11): p. 8189-8209.
11. Marlatt, M.W., et al., *Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies.* J Alzheimers Dis, 2008. **15**(2): p. 199-210.
12. Cheah, I.K. and B. Halliwell, *Ergothioneine; antioxidant potential, physiological function and role in disease.* Biochim Biophys Acta, 2012. **1822**(5): p. 784-93.
13. Wu, L.Y., et al., *Low plasma ergothioneine levels are associated with neurodegeneration and cerebrovascular disease in dementia.* Free Radic Biol Med, 2021. **177**: p. 201-211.
14. Chong, J.R., et al., *Plasma P-tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease.* Alzheimers Dement, 2021. **17**(10): p. 1649-1662.
15. Karikari, T.K., et al., *Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.* The Lancet Neurology, 2020. **19**(5): p. 422-433.
16. Feng, W., et al., *NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing.* Nat Commun, 2023. **14**(1): p. 7238.
17. Chong, J.R., et al., *Clinical utility of plasma p-tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease.* Alzheimers Dement, 2025. **21**(2): p. e14502.
18. Ashton, N.J., et al., *Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring.* Nat Med, 2022. **28**(12): p. 2555-2562.
19. Guglielmotto, M., et al., *Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors.* Front Aging Neurosci, 2010. **2**: p. 3.

20. Abramov, A.Y., L. Canevari, and M.R. Duchen, *Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase.* J Neurosci, 2004. **24**(2): p. 565-75.
21. Butterfield, D.A. and B. Halliwell, *Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease.* Nat Rev Neurosci, 2019. **20**(3): p. 148-160.
22. Halliwell, B. and I. Cheah, *Are age-related neurodegenerative diseases caused by a lack of the diet-derived compound ergothioneine?* Free Radic Biol Med, 2024. **217**: p. 60-67.
23. Cheah, I.K., et al., *Administration of Pure Ergothioneine to Healthy Human Subjects: Uptake, Metabolism, and Effects on Biomarkers of Oxidative Damage and Inflammation.* Antioxid Redox Signal, 2017. **26**(5): p. 193-206.
24. Servillo, L., et al., *An uncommon redox behavior sheds light on the cellular antioxidant properties of ergothioneine.* Free Radic Biol Med, 2015. **79**: p. 228-36.
25. Farina, N., et al., *Vitamin E for Alzheimer's dementia and mild cognitive impairment.* Cochrane Database Syst Rev, 2017. **1**(1): p. Cd002854.
26. Galasko, D.R., et al., *Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures.* Arch Neurol, 2012. **69**(7): p. 836-41.
27. Knight, E., et al., *The Role of Dietary Antioxidants and Their Potential Mechanisms in Alzheimer's Disease Treatment.* Metabolites, 2023. **13**(3).
28. Persson, T., B.O. Popescu, and A. Cedazo-Minguez, *Oxidative stress in Alzheimer's disease: why did antioxidant therapy fail?* Oxid Med Cell Longev, 2014. **2014**: p. 427318.
29. Nakamichi, N. and Y. Kato, *Physiological Roles of Carnitine/Organic Cation Transporter OCTN1/SLC22A4 in Neural Cells.* Biol Pharm Bull, 2017. **40**(8): p. 1146-1152.
30. Cheah, I.K. and B. Halliwell, *Ergothioneine, recent developments.* Redox Biology, 2021. **42**: p. 101868.
31. Tian, X., J.L. Thorne, and J.B. Moore, *Ergothioneine: an underrecognised dietary micronutrient required for healthy ageing?* Br J Nutr, 2023. **129**(1): p. 104-114.
32. Syahputra, R.A., et al., *Ergothioneine as a functional nutraceutical: Mechanisms, bioavailability, and therapeutic implications.* J Nutr Biochem, 2025. **145**: p. 110006.
33. Takhor, N.H. and C.W. Phan, *The role of Ergothioneine in cognition and age-related neurodegenerative disease: a systematic review.* Inflammopharmacology, 2025. **33**(5): p. 2351-2375.
34. Shi, C., et al., *Ergothioneine Stimulates Ca(2+)-Mediated Brain-Derived Neurotrophic Factor Expression in NE-4C Nerve Cells.* ACS Omega, 2025. **10**(7): p. 7004-7012.
35. Palmqvist, S., et al., *Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.* JAMA, 2020. **324**(8): p. 772-781.